文献速递肿瘤 PET/CT神经核医学

68Ga-DOTA偶联生长抑素受体靶向肽PET检测嗜铬细胞瘤和副神经节瘤的性能:系统评价与荟萃分析

Performance of 68Ga-DOTA-Conjugated Somatostatin Receptor-Targeting Peptide PET in Detection of Pheochromocytoma and Paraganglioma: A Systematic Review and Metaanalysis.
PubMed 文献 · J Nucl Med · 2018-07-20

该系统评价与荟萃分析检索PubMed和Embase至2018年5月8日,纳入报告68Ga-DOTA-SST PET在PPGL患者中检出率的研究。13项研究纳入定性合成,9项研究(215例患者)定量合成,汇总检出率为93%(95%CI 91%-95%),显著高于18F-FDOPA PET、18F-FDG PET和123/131I-MIBG扫描。作者认为68Ga-DOTA-SST PET在PPGL病灶检测中表现优于其他功能影像,但多血/副神经节瘤综合征患者除外。

要点

  • 68Ga-DOTA-SST PET汇总检出率为93%(95%CI 91%-95%),显著高于18F-FDOPA PET的80%(95%CI 69%-88%)。
  • 68Ga-DOTA-SST PET检出率亦显著高于18F-FDG PET的74%(95%CI 46%-91%)和123/131I-MIBG扫描的38%(95%CI 20%-59%),P<0.001。
  • 多血/副神经节瘤综合征患者中68Ga-DOTA-DOTATATE PET检出率为35%;头颈部副神经节瘤比例越高,68Ga-DOTA-SST PET检出率越高(P=0.0002)。

核心结论

  • 68Ga-DOTA-SST PET在PPGL患者病灶检测中表现优于其他功能影像方法,但多血/副神经节瘤综合征患者除外。
  • 作者认为这可能提示68Ga-DOTA-SST PET可作为PPGL原发分期或遗传状态未知时再分期的首选影像方法。

研究设计与样本

  • 系统评价与荟萃分析,检索PubMed和Embase截至2018年5月8日。
  • 纳入报告68Ga-DOTA-SST PET在PPGL患者中检出率的研究,13项研究纳入定性合成。
  • 9项无特定亚型纳入标准的研究(215例患者)进行定量合成,采用随机效应模型汇总检出率。
  • 进行亚组分析和荟萃回归以探索异质性原因。

主要发现

  • 68Ga-DOTA-SST PET的每病灶检出率持续高于其他影像方法,范围为92%至100%。
  • 9项研究(215例患者)汇总检出率为93%(95%CI 91%-95%),显著高于18F-FDOPA PET的80%(95%CI 69%-88%)、18F-FDG PET的74%(95%CI 46%-91%)和123/131I-MIBG扫描的38%(95%CI 20%-59%),P<0.001。
  • 多血/副神经节瘤综合征患者中68Ga-DOTA-DOTATATE PET检出率为35%。
  • 头颈部副神经节瘤比例较高与68Ga-DOTA-SST PET检出率较高相关(P=0.0002)。

临床怎么用

  • 作者认为68Ga-DOTA-SST PET可能作为PPGL原发分期或遗传状态未知时再分期的首选影像方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We performed a systematic review and metaanalysis of the performance of 68Ga-DOTA-conjugated somatostatin receptor-targeting peptide (68Ga-DOTA-SST) PET in the detection of pheochromocytomas and paragangliomas (PPGLs). Methods: PubMed and Embase were searched until May 8, 2018. We included studies that reported the detection rate of 68Ga-DOTA-SST PET in patients with PPGLs. Detection rates were pooled using a random-effects model. Subgroup analyses and metaregression were performed to explore the cause of heterogeneity. Results: Thirteen studies were included for qualitative synthesis. Per-lesion detection rates of 68Ga-DOTA-SST PET were consistently higher (ranging from 92% to 100%) than other imaging modalities, including 18F-fluorohydroxyphenylalanine (18F-FDOPA) PET, 18F-FDG PET, and 123/131I-metaiodobenzylguanidine (123/131I-MIBG) scintigraphy. However, in patients with polycythemia/paraganglioma syndrome, the detection rate of 68Ga-DOTA-DOTATATE PET was 35%. Nine studies (215 patients) with no specific inclusion criteria for subtype were quantitatively synthesized. The pooled detection rate was 93% (95% confidence interval [CI], 91%-95%), which was significantly higher than that of 18F-FDOPA PET (80% [95% CI, 69%-88%]), 18F-FDG PET (74% [95% CI, 46%-91%]), and 123/131I-MIBG scan (38% [95% CI, 20%-59%], P < 0.001 for all). A greater prevalence of head and neck paragangliomas was associated with higher detection rates of 68Ga-DOTA-SST PET (P = 0.0002). Conclusion:68Ga-DOTA-SST PET exhibited superior performance for lesion detection, over other functional imaging modalities, in patients with PPGLs, with the exception of polycythemia/paraganglioma syndrome. This might suggest 68Ga-DOTA-SST PET as a first-line imaging modality for the primary staging of PPGL or the restaging of PPGL with unknown genetic status.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Han S, Suh CH, Woo S, et al. Performance of 68Ga-DOTA-Conjugated Somatostatin Receptor-Targeting Peptide PET in Detection of Pheochromocytoma and Paraganglioma: A Systematic Review and Metaanalysis. J Nucl Med. 2018. PMID: 30030341. doi:10.2967/jnumed.118.211706

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。